Search alternatives:
significant point » significant amount (Expand Search), significant part (Expand Search), significant event (Expand Search)
point decrease » point increase (Expand Search)
size decrease » sizes decrease (Expand Search), size increase (Expand Search), size increased (Expand Search)
significant point » significant amount (Expand Search), significant part (Expand Search), significant event (Expand Search)
point decrease » point increase (Expand Search)
size decrease » sizes decrease (Expand Search), size increase (Expand Search), size increased (Expand Search)
-
1
-
2
Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size.
Published 2025“…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”
-
3
-
4
-
5
-
6
Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization
Published 2025“…This study investigated clinical characteristics and outcomes associated with longitudinal decreases in LV size in this population. Methods: We analyzed echocardiographic data from 6,232 adults with normal baseline left ventricular end-diastolic diameter (LVEDD), with a mean interval of 4.8 years between baseline and follow-up echocardiograms. …”
-
7
-
8
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
9
-
10
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
11
-
12
-
13
-
14
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
15
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
16
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
17
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
18
-
19
-
20
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: